{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:42:41Z","timestamp":1791852161311,"version":"4.3.4"},"reference-count":59,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Antibiotic resistance in bacteria is ever changing and adapting, as once-novel \u03b2-lactam antibiotics are losing their efficacy, primarily due to the production of \u03b2-lactamases. Metallo-\u03b2-lactamases (MBLs) efficiently inactivate a broad range of \u03b2-lactam antibiotics, including carbapenems, and are often coexpressed with other antibacterial resistance factors. The rapid dissemination of MBLs and lack of novel antibacterials pose an imminent threat to global health. In an effort to better counter these resistance-conferring \u03b2-lactamases, an investigation of their natural evolution and resulting substrate specificity was employed. In this study, we elucidated the effects of different amino acid substitutions at position 67 in IMP-type MBLs on the ability to hydrolyze and confer resistance to a range of \u03b2-lactam antibiotics. Wild-type \u03b2-lactamases IMP-1 and IMP-10 and mutants IMP-1-V67A and IMP-1-V67I were characterized biophysically and biochemically, and MICs for\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Escherichia coli<\/jats:named-content>\n            cells expressing these enzymes were determined. We found that all variants exhibited catalytic efficiencies (\n            <jats:italic>k<\/jats:italic>\n            <jats:sub>cat<\/jats:sub>\n            \/\n            <jats:italic>\n              K\n              <jats:sub>m<\/jats:sub>\n            <\/jats:italic>\n            ) equal to or higher than that of IMP-1 against all tested \u03b2-lactams except penicillins, against which IMP-1 and IMP-1-V67I showed the highest\n            <jats:italic>k<\/jats:italic>\n            <jats:sub>cat<\/jats:sub>\n            \/\n            <jats:italic>\n              K\n              <jats:sub>m<\/jats:sub>\n            <\/jats:italic>\n            values. The substrate-specific effects of the different amino acid substitutions at position 67 are discussed in light of their side chain structures and possible interactions with the substrates. Docking calculations were employed to investigate interactions between different side chains and an inhibitor used as a \u03b2-lactam surrogate. The differences in binding affinities determined experimentally and computationally seem to be governed by hydrophobic interactions between residue 67 and the inhibitor and, by inference, the \u03b2-lactam substrates.\n          <\/jats:p>","DOI":"10.1128\/aac.01651-15","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T01:51:14Z","timestamp":1442281874000},"page":"7299-7307","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":30,"title":["Elucidating the Role of Residue 67 in IMP-Type Metallo-\u03b2-Lactamase Evolution"],"prefix":"10.1128","volume":"59","author":[{"given":"Alecander E.","family":"LaCuran","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Pegg","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, California State Polytechnic University, Pomona, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor M.","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Bethel","sequence":"additional","affiliation":[{"name":"Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Ai","sequence":"additional","affiliation":[{"name":"Pharmaceutical Informatics Institute, School of Pharmaceutical Sciences, Zhejiang University, Zhejiang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Welsh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, and Division of Chem Informatics, Biomedical Informatics Shared Resource, Rutgers-Cancer Institute of New Jersey, Piscataway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Bonomo","sequence":"additional","affiliation":[{"name":"Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA"},{"name":"Departments of Medicine, Pharmacology, Biochemistry, and Molecular Biology &amp; Microbiology, Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Oelschlaeger","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.1980.0049"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.4.902"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1110\/ps.041093405"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/1040841X.2011.559944"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2012.717712"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.660-663.2001"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.7.2347-2349.2004"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2010.09.006"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70056-1"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2009.03116.x"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm9012938"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-micro-090110-102911"},{"key":"e_1_3_3_14_2","volume-title":"\u03b2-Lactamase classification and amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant enzymes","author":"Bush K","year":"2015","unstructured":"Bush K, Palzkill TG, Jacoby GA. 2015. \u03b2-Lactamase classification and amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant enzymes. Lahey Clinic, Burlington, MA. http:\/\/www.lahey.org\/studies\/other.asp-table1. Accessed 6 July 2015."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.1.71"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.1.147"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)75604-X"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2004.04.007"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.12.5407-5413.2003"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.2014-2016.2002"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01905-09"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00716-13"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics3030285"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi992569m"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi990986t"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-5521(03)00070-X"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02341-12"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2004.09.074"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2013.07.028"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm701031n"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.355-358.2006"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt004"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku133"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01440-12"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(85)90409-9"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi001860v"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi100232q"},{"key":"e_1_3_3_38_2","volume-title":"M07-A9","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, ninth edition. M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/pro.2530"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm030242k"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1021\/Ja00299a024"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi050801k"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/prot.340230104"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb00174.x"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2005.04.044"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkh371"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/bip.20853"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(86)90241-1"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1006\/abio.2000.4880"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5238.935"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s008940100038"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00255-12"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20080375"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja303579d"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja508388e"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi0300332"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00423-13"},{"key":"e_1_3_3_59_2","doi-asserted-by":"crossref","unstructured":"Oelschlaeger P Toney JH. 13 October 2009. Are human microflora influenced by environmental exposure to antibiotics? Science http:\/\/www.sciencemag.org\/content\/325\/5944\/1128\/reply. Accessed 8 July 2015.","DOI":"10.1126\/science.1176950"},{"key":"e_1_3_3_60_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-3-540-74664-5_4","volume-title":"Pharmaceuticals in the environment: sources, fate, effects and risks","author":"Kuemmerer K","year":"2008","unstructured":"Kuemmerer K. 2008. Substance flow associated with medical care\u2014significance of different sources, p 43\u201359. In Pharmaceuticals in the environment: sources, fate, effects and risks. Springer, Berlin, Germany."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01651-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01651-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:01:05Z","timestamp":1645484465000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01651-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1128\/AAC.01651-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.01651-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"2015-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-09-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}